$ANTX News

AN2 Therapeutics, Inc. Reports Inducement Grants Under Listing Rule 5635(c)(4)

AN2 Therapeutics to Present Phase 2 Design for Epetraborole in Polycythemia Vera at the 18th International Congress on Myeloproliferative Neoplasms

AN2 Therapeutics to Participate at Upcoming Investor Conferences

GSK (LSE:GSK) The Latest Update Raises A Bigger Question

AN2 Therapeutics Announces Extension of Funding for Tuberculosis Research Collaboration with GSK

AN2 Therapeutics: A Failed Drug Could Become A Major Value Driver

AN2 Therapeutics, Inc. Reports Inducement Grants under Listing Rule 5635(c)(4)

AN2 Therapeutics To Reveal Clinical and Translational Data Supporting Development of Epetraborole for Polycythemia Vera At The SOHO 2026 Annual Meeting

AN2 Therapeutics Appoints Cameron Trenor, M.D., as Chief Medical Officer

AN2 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business and Scientific Highlights

AN2 Therapeutics Q2 EPS $(0.18) Beats $(0.27) Estimate

Guggenheim Initiates Coverage On AN2 Therapeutics with Buy Rating, Announces Price Target of $9

AN2 Therapeutics Reports Positive Enabling Data Supporting Advancement of Oral AN2-502998 to Phase 2 Study for Chronic Chagas Disease

AN2 Therapeutics Announces Results From Two Studies Evaluating Its Oral CPSF3 Inhibitor, AN2-502998, For The Treatment Of Chronic Chagas Disease; Parasites Eliminated With 28-Day Treatment In 100% Of Nonhuman Primates

AN2 Therapeutics Announces Results From Two Studies Evaluating Oral CPSF3 Inhibitor, AN2-502998, For Treatment Of Chronic Chagas Disease Caused By Infection With Parasite T. Cruzi

AN2 Therapeutics to Present at 2026 Jefferies Global Healthcare Conference

Leerink Partners Upgrades AN2 Therapeutics to Outperform, Announces $9 Price Target

AN2 Therapeutics Inc (NASDAQ:ANTX) Pipeline Progress Outshines Slight Q1 Earnings Miss

AN2 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business and Scientific Highlights

AN2 Therapeutics Enters Open Market Sale Agreement With Jefferies Dated April 9, 2026; Co. May Offer And Sell Common Stock Up To $80M Through Jefferies